# A Study for the Treatment of Diabetic Peripheral Neuropathic Pain

> **NCT00552175** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 339 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** Duloxetine hydrochloride - 40 mg
- **DRUG:** placebo
- **DRUG:** Duloxetine hydrochloride - 60 mg

## Key facts

- **NCT ID:** NCT00552175
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2010-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552175, "A Study for the Treatment of Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00552175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*